- Home
- RGC vs EARN Comparison
RGC vs EARN Comparison
Compare RGC & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- EARN
- Stock Information
- Founded
- RGC 2014
- EARN 2012
- Country
- RGC Hong Kong
- EARN United States
- Employees
- RGC N/A
- EARN N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- EARN Real Estate Investment Trusts
- Sector
- RGC Health Care
- EARN Real Estate
- Exchange
- RGC Nasdaq
- EARN Nasdaq
- Market Cap
- RGC 8.4B
- EARN 189.7M
- IPO Year
- RGC 2021
- EARN 2013
- Fundamental
- Price
- RGC $16.45
- EARN $5.05
- Analyst Decision
- RGC
- EARN Buy
- Analyst Count
- RGC 0
- EARN 2
- Target Price
- RGC N/A
- EARN $5.88
- AVG Volume (30 Days)
- RGC 202.7K
- EARN 338.2K
- Earning Date
- RGC 10-24-2025
- EARN 11-19-2025
- Dividend Yield
- RGC N/A
- EARN 18.46%
- EPS Growth
- RGC N/A
- EARN N/A
- EPS
- RGC N/A
- EARN N/A
- Revenue
- RGC N/A
- EARN $35,893,000.00
- Revenue This Year
- RGC N/A
- EARN N/A
- Revenue Next Year
- RGC N/A
- EARN $15.93
- P/E Ratio
- RGC N/A
- EARN N/A
- Revenue Growth
- RGC N/A
- EARN 43.30
- 52 Week Low
- RGC $0.09
- EARN $4.33
- 52 Week High
- RGC $83.60
- EARN $6.99
- Technical
- Relative Strength Index (RSI)
- RGC 47.18
- EARN 35.68
- Support Level
- RGC $15.79
- EARN $5.10
- Resistance Level
- RGC $17.45
- EARN $5.40
- Average True Range (ATR)
- RGC 1.09
- EARN 0.08
- MACD
- RGC -0.02
- EARN 0.01
- Stochastic Oscillator
- RGC 33.05
- EARN 23.11
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.